- Conditions
- Gastroesophageal Reflux, Dysphagia, Esophageal Motility Disorders
- Interventions
- diaphragmatic breathing
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer (CRC), Gastric Cancer
- Interventions
- SC-007
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Rochester, Minnesota • St Louis, Missouri + 4 more
- Conditions
- Esophageal Cancer, Esophagogastric Junction Cancer
- Interventions
- Intravenous Tislelizumab, Chemotherapy, Fractionated radiation, Esophagectomy
- Drug · Radiation · Procedure
- Lead sponsor
- Zhonglin Hao
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
- Interventions
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
- Genetic
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2037
- U.S. locations
- 9
- States / cities
- Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
- Interventions
- E-602, Cemiplimab
- Biological
- Lead sponsor
- Palleon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- La Jolla, California • Los Angeles, California • Stanford, California + 10 more